MiMedx Group faces a severe operational inflection, with revenue contracting 34.7% year-over-year in 2026Q2 and gross margins compressing 1,490 basis points from their 2025Q4 peak to 69.0%, indicating significant pricing pressure and volume deleverage. The com...
Price trend, volume and key moving averages
Trailing total returns as of 9/24/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC).
Check whether operating performance supports the current valuation.
Recent results and news deserve attention only when they alter the forward view.
| Quarter | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|
Q3 2026Latest Jul 29, 2026 | -$0.05-1.0% vs -$0.05 | $64M+1.4% vs $63M |
Q2 2026 Apr 29, 2026 | -$0.05+28.6% vs -$0.07 | $59M-10.3% vs $66M |
Q1 2026 Feb 25, 2026 | $0.14+55.6% vs $0.09 | $118M+10.6% vs $107M |
Q4 2025 Oct 29, 2025 | $0.15+114.3% vs $0.07 | $114M+11.6% vs $102M |
MARIETTA, Ga., Sept. 08, 2026 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”) today announced that members of its senior management will participate in the following investor conferences:
Deutsche Bank AG bought a new position in shares of MiMedx Group, Inc (NASDAQ: MDXG) in the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm bought 135,153 shares of the company's stock, valued at approximately $520,000. Deutsche Bank AG owned about
MiMedx Group, Inc. (MDXG) Q2 2026 Earnings Call Transcript
MiMedx Group NASDAQ: MDXG said it has agreed to acquire Sanara MedTech in a transaction valued at $35 per Sanara share, a deal the company expects to close by the end of 2026. The announcement accompanied MiMedx's second-quarter results, which showed sequential improvement in its wound-care business and continued growth in surgical sales.
Benchmark MDXG against direct peers instead of judging its metrics in isolation.
Key metrics vs top competitors for MiMedx Group, Inc. (MDXG)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $4.77 | $695.28M | 14.91 | 19.99% | 11.6% | 21.61% | — | |
| $0.95 | $121.39M | -2.03 | — | -29747.89% | -37.58% | — | |
| $3.99 | $274.71M | -4.24 | -38.1% | -43.7% | -14.73% | — | |
| $1.30 | $58.16M | -1.57 | 15.84% | -51.53% | — | — | |
| $36.78 | $767.54M | 14.60 | 3.21% | 4.88% | 13.43% | — | |
| $179.95 | $9.42B | -64.27 | -27.1% | 4.9% | 9.08% | — |
MiMedx Group, Inc. (MDXG) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
Verify the primary filings, follow material updates, and answer the remaining questions.
MiMedx Group, Inc. (MDXG) SEC filings — annual & quarterly reports (10-K, 10-Q)
Jul 29, 2026·SEC
Jul 29, 2026·SEC
Jun 16, 2026·SEC
Get notified when MDXG posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
MiMedx Group, Inc. (MDXG) stock FAQ — growth, dividends, profitability & financials explained
MiMedx Group, Inc. (MDXG) reported $355.2M in revenue for fiscal year 2025.
MiMedx Group, Inc. (MDXG) grew revenue by 20.0% over the past year. This is strong growth.
Yes, MiMedx Group, Inc. (MDXG) is profitable, generating $6.2M in net income for fiscal year 2025 (11.6% net margin).
MiMedx Group, Inc. (MDXG) has a return on equity (ROE) of 21.6%. This is excellent, indicating efficient use of shareholder capital.
MiMedx Group, Inc. (MDXG) generated $40.6M in free cash flow for fiscal year 2025. Positive FCF indicates the company can fund dividends, buybacks, or reinvestment.
